Coagulation and Transfusion Updates From 2021.

Similarly, there was a nonsignificant trend toward higher LVAD pump thrombosis with PCC (2.6% v 0.8%, p = 0.98). 33 In another retrospective investigation of activated PCC (factor VIII inhibitor bypassing activity [FEIBA]) for post-LVAD coagulopathy, FEIBA use was associated with no increase in 14-day thrombotic outcomes (11.0% v 7.6%, p = 0.343) or mortality rate (3.7% v 1.3%, p = 0.179). 34 Although the authors suggested a favorable risk-benefit profile for FEIBA use in LVAD surgery, they acknowledged that future studies still are required to fully assess the safety profile.

also in 5,406 other papers

A retrospective analysis of 160 LVAD patients found that PCC use decreased the need for intraoperative transfusion when compared to no PCC; however, this difference did not reach statistical significance.

also in 111,027 other papers